Ghent University Academic Bibliography

Advanced

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells

Yannick Willemen, Johan M. J. Van den Bergh, Sarah Bonte UGent, Sebastien Anguille, Carlo Heirman, Barbara MH Stein, Herman Goossens, Tessa Kerre UGent, Kris Thielemans, Marc Peeters, et al. (2016) ONCOTARGET. 7(45). p.73960-73970
abstract
We formerly demonstrated that vaccination with Wilms' tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we could introduce the receptor for hyaluronic acid-mediated motility (RHAMM/HMMR/CD168), another clinically relevant tumor-associated antigen, into these mo-DCs through mRNA electroporation and elicit RHAMM-specific immune responses. While RHAMM mRNA electroporation significantly increased RHAMM protein expression by mo-DCs, our data indicate that classical mo-DCs already express and present RHAMM at sufficient levels to activate RHAMM-specific T cells, regardless of electroporation. Moreover, we found that RHAMM-specific T cells are present at vaccination sites in AML patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
ACUTE MYELOID-LEUKEMIA, HYALURONAN-MEDIATED MOTILITY, CHRONIC, LYMPHOCYTIC-LEUKEMIA, PEPTIDE VACCINATION, MULTIPLE-MYELOMA, MYELODYSPLASTIC SYNDROME, COLORECTAL-CANCER, MESSENGER-RNA, IN-VIVO, RECEPTOR, electroporation, hyaluronan-mediated motility receptor, immunotherapy, messenger RNA, vaccination
journal title
ONCOTARGET
Oncotarget
volume
7
issue
45
pages
73960 - 73970
Web of Science type
Article
Web of Science id
000387452100115
JCR category
ONCOLOGY
JCR impact factor
5.168 (2016)
JCR rank
44/217 (2016)
JCR quartile
1 (2016)
ISSN
1949-2553
DOI
10.18632/oncotarget.12170
language
English
UGent publication?
yes
classification
A1
copyright statement
I have retained and own the full copyright for this publication
id
8509452
handle
http://hdl.handle.net/1854/LU-8509452
date created
2017-02-14 14:41:34
date last changed
2017-02-22 13:48:34
@article{8509452,
  abstract     = {We formerly demonstrated that vaccination with Wilms' tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we could introduce the receptor for hyaluronic acid-mediated motility (RHAMM/HMMR/CD168), another clinically relevant tumor-associated antigen, into these mo-DCs through mRNA electroporation and elicit RHAMM-specific immune responses. While RHAMM mRNA electroporation significantly increased RHAMM protein expression by mo-DCs, our data indicate that classical mo-DCs already express and present RHAMM at sufficient levels to activate RHAMM-specific T cells, regardless of electroporation. Moreover, we found that RHAMM-specific T cells are present at vaccination sites in AML patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM.},
  author       = {Willemen, Yannick and Van den Bergh, Johan M. J. and Bonte, Sarah and Anguille, Sebastien and Heirman, Carlo and Stein, Barbara MH and Goossens, Herman and Kerre, Tessa and Thielemans, Kris and Peeters, Marc and Van Tendeloo, Viggo FI and Smits, Evelien LJ and Berneman, Zwi N},
  issn         = {1949-2553},
  journal      = {ONCOTARGET},
  keyword      = {ACUTE MYELOID-LEUKEMIA,HYALURONAN-MEDIATED MOTILITY,CHRONIC,LYMPHOCYTIC-LEUKEMIA,PEPTIDE VACCINATION,MULTIPLE-MYELOMA,MYELODYSPLASTIC SYNDROME,COLORECTAL-CANCER,MESSENGER-RNA,IN-VIVO,RECEPTOR,electroporation,hyaluronan-mediated motility receptor,immunotherapy,messenger RNA,vaccination},
  language     = {eng},
  number       = {45},
  pages        = {73960--73970},
  title        = {The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells},
  url          = {http://dx.doi.org/10.18632/oncotarget.12170},
  volume       = {7},
  year         = {2016},
}

Chicago
Willemen, Yannick, Johan M. J. Van den Bergh, Sarah Bonte, Sebastien Anguille, Carlo Heirman, Barbara MH Stein, Herman Goossens, et al. 2016. “The Tumor-associated Antigen RHAMM (HMMR/CD168) Is Expressed by Monocyte-derived Dendritic Cells and Presented to T Cells.” Oncotarget 7 (45): 73960–73970.
APA
Willemen, Y., Van den Bergh, J. M. J., Bonte, S., Anguille, S., Heirman, C., Stein, B. M., Goossens, H., et al. (2016). The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. ONCOTARGET, 7(45), 73960–73970.
Vancouver
1.
Willemen Y, Van den Bergh JMJ, Bonte S, Anguille S, Heirman C, Stein BM, et al. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. ONCOTARGET. 2016;7(45):73960–70.
MLA
Willemen, Yannick, Johan M. J. Van den Bergh, Sarah Bonte, et al. “The Tumor-associated Antigen RHAMM (HMMR/CD168) Is Expressed by Monocyte-derived Dendritic Cells and Presented to T Cells.” ONCOTARGET 7.45 (2016): 73960–73970. Print.